18 documents found, page 1 of 2
Consensus for the Early Identification of Secondary Progressive Multiple Sclero...
Sá, MJ; Basílio, C; Capela, C; Cerqueira, JJ; Mendes, I; Morganho, A; Correia de Sá, J; Salgado, V; Martins Silva, A; Vale, J; Sousa, LIntroduction: Multiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools applicable in the transition phase from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis. We aimed to reach a Portuguese national con...
Influence of Physicians’ Risk Perception on Switching Treatments Between High- ...
Seifer, G; Arun, T; Capela, C; Laureys, G; Jones, E; Dominguez-Castro, P; Sanchez-de la Rosa, R; Hiltl, S; Iaffaldano, PBackground: The decision of initiating treatment for multiple sclerosis (MS) with a high-efficacy DMT (HE DMT) or non-high-efficacy DMT (non-HE DMT) is influenced by several factors, including risk perception of patients and physicians. Objective: Investigate the influence of physicians' risk perception on decision-making when switching treatments for MS and the reasons for switching. Methods: Data were drawn f...
Cost-Effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and P...
Martins, P; Vandewalle, B; Félix, J; Capela, C; Cerqueira, JJ; Salgado, AV; Ferreira, DG; Monteiro, IObjectives: Ocrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosis (MS), an incurable disease characterized by disability progression. This study evaluated the clinical and economic impact of ocrelizumab relative to current clinical practice, including other disease-modifying therapies (DMT), available in Portugal. Methods: Ma...
Fingolimod Treatment Modulates PPARγ and CD36 Gene Expression in Women with Mul...
Ferret-Sena, V; Capela, C; Macedo, A; Salgado, AV; Derudas, B; Staels, B; Sena, AFingolimod is an oral immunomodulatory drug used in the treatment of multiple sclerosis (MS) that may change lipid metabolism. Peroxisome proliferator-activated receptors (PPAR) are transcription factors that regulate lipoprotein metabolism and immune functions and have been implicated in the pathophysiology of MS. CD36 is a scavenger receptor whose transcription is PPAR regulated. The objective of this study w...
Seroconversion Rate Following HBV Vaccination in Clinical Practice: The Role of...
Faustino, P; Coutinho, M; Leitão, L; Capela, C; Brum, M; Parra, J; Sequeira, J; Barros, A; Araújo, C; Sousa, A; Ladeira, FHBV screening and immunization is recommended in all MS patients and is mandatory before the start of some DMT. However, studies evaluating the immune response to HBV vaccine in MS patients are scarce. We aimed to evaluate the seroprotection rate following HBV immunization in MS patients and to assess if older age and DMT-treatment influenced seroprotection. We conducted a cohort study between 2016 and 2020 and...
Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis...
Barros, A; Sequeira, J; Sousa, A; Parra, J; Brum, M; Pedrosa, R; Capela, CObjectives: The aim of this study was to evaluate postmarketing dimethyl fumarate (DMF) safety and effectiveness in a real-world population with relapsing-remitting multiple sclerosis (RRMS). Methods: This was a retrospective, single-center study with RRMS patients treated with DMF. Demographic, clinical, and imagiological characteristics were analyzed, including annualized relapse rate (ARR), Expanded Disabili...
Serum Lipoprotein Profile Is Associated With Protective Effects of Oral Contrac...
Sena, A; Macedo, A; Ferret-Sena, V; Capela, C; Pedrosa, RBackground: The mechanisms underlying the influence of sex hormones in multiple sclerosis (MS) are uncertain. Sex steroids interact with cholesterol metabolism and the serum lipid profile has been associated with the severity of the disease. We hypothesized that the putative associations between lipoprotein metabolism and MS could be modulated by sex steroids exposure. The aim of this study was to investigate w...
A Multicenter, Non-Interventional Study to Evaluate the Disease Activity in Mul...
Ladeira, F; Braz, L; Salgado, P; Vaz, S; Leitão, L; Félix, C; Correia, AS; Martins da Silva, A; Salgado, V; Ferreira, F; Vale, J; Sá, MJ; Capela, CObjectives: Natalizumab (NTZ) is very effective for treatment of relapsing-remitting multiple sclerosis (RRMS), its use is mainly limited by safety issues. Discontinuation of NTZ is associated with recurrence of disease activity (reactivation and rebound). The best strategy for subsequent therapy and the predictive factors for recurrence in such patients are areas of active research. We aimed to evaluate predic...
Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in...
Ferret-Sena, V; Capela, C; Sena, AMultiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system (CNS) probably caused, in most cases, by the interaction of genetic and environmental factors. This review first summarizes some clinical, epidemiological and pathological characteristics of MS. Then, the involvement of biochemical pathways is discussed in the development and repair of the CNS lesions and the ...
Autoimmune diseases and pregnancy: analysis of a series of cases.
Gomes, V; Mesquita, A; Capela, CBACKGROUND: An autoimmune disease is characterized by tissue damage, caused by self-reactivity of different effector mechanisms of the immune system, namely antibodies and T cells. All autoimmune diseases, to some extent, have implications for fertility and obstetrics. Currently, due to available treatments and specialised care for pregnant women with autoimmune disease, the prognosis for both mother and child ...